Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 27Irinotecan 8Filgrastim 8Carmustine 7Carboplatin 7Surgical Procedures, Operative 6O(6)-benzylguanine 6Flucytosine 6sargramostim 4Vorinostat 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4vocimagene amiretrorepvec 3lonafarnib 3Radiosurgery 3Lenalidomide 3Imatinib Mesylate 3Genetic Therapy 3Erlotinib Hydrochloride 3Cyclophosphamide 3Bortezomib 3temsirolimus 2cediranib 2aldesleukin 2Vincristine 2Vinblastine 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Oligodendroglioma × regadenoson × Clear all
NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡